Status:
COMPLETED
Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma
Lead Sponsor:
Novartis
Conditions:
Treatment of Bone Metastases
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Zoledronic acid is a medication that slows the breakdown of bone. This study will assess the efficacy and safety of zoledronic acid in Chinese patients with multiple myeloma or other solid tumors with...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Cancer patients (multiple myeloma or other solid tumors) and confirmed evidence of bone lesions
- Significant bone pain
- Exclusion Criteria
- Poor renal function
- Use of other investigational drugs within 30 days of visit 2
- Dental or other surgery to the jaw within 6 weeks of screening, or planned during the 4 week study
- Other protocol-defined exclusion criteria may apply.
Exclusion
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT00219258
Start Date
July 1 2005
Last Update
November 23 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing
Beijing, China